| Inflammasome-mediated caspase-1 activity Gatekeeper of inflammation in the adipose tissue |
| | Obesity promotes the development of insulin resistance and type 2 diabetes |
|
| Obesity, the adipose tissue and type 2 diabetes |
| | Adipose tissue as an endocrine organ secretion of a wide variety of ‘adipokines’ |
|
| Adipose tissue inflammation |
| | The pro-inflammatory cytokine IL-1β and Type 2 Diabetes Current knowledge |
|
| The NLRP3-inflammasome controls IL-1β release |
| | Is caspase-1 present in adipose tissue and regulated during obesity ? |
|
| Caspase-1 activation in adipose tissue is accompanied by increased levels of IL-1β |
| | High fat diet-induced obesity in caspase-1-/- animals |
|
| Adipose tissue inflammation in HFD-fed wild-type and caspase-1-/- animals |
| | Improvement in systemic insulin sensitivity in the absence of caspase-1 ? |
|
| Inhibition of caspase-1 in obese and insulin resistant animals ? |
| | Insulin sensitivity is robustly improved in Ob/Ob animals after 2 weeks of caspase-1 inhibition |
|
| The inflammasome and caspase-1 in human adipose tissue |
| | IL-1β secretion by human VAT vs. SAT ? |
|
| Inhibition of caspase-1 specifically inhibits IL-1β production by VAT |
| | Summary |
|
| Future perspective Identification of potential triggers of inflammasome activation |
| | Conclusion |
|
Deel deze pagina met collega's en vrienden: